Literature DB >> 11398102

Natural measles causes prolonged suppression of interleukin-12 production.

S F Atabani1, A A Byrnes, A Jaye, I M Kidd, A F Magnusen, H Whittle, C L Karp.   

Abstract

Among vaccine-preventable diseases, measles is the preeminent killer of children worldwide. Infection with measles virus (MV) is associated with prolonged suppression of cell-mediated immune responses, a phenomenon that is thought to underlie the susceptibility to secondary infections that accounts for most measles-related mortality. Interleukin (IL)-12 is critical for the orchestration of cellular immunity. MV specifically ablates IL-12 production by monocyte/macrophages in vitro through binding to CD46, a complement regulatory protein that is an MV receptor. To address the effect of MV on IL-12 responses in vivo, cytokine production was examined in Gambian patients with measles. IL-12 production by peripheral blood monocytes from such patients is markedly suppressed, which provides a unifying mechanism for many of the immunologic abnormalities associated with measles. This suppression is prolonged, with significant, stimulus-specific inhibition of IL-12 production demonstrable months after recovery from acute infection. However, despite this suppression, IL-12 responsiveness remains intact.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11398102     DOI: 10.1086/321009

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  26 in total

1.  The Reemergence of Measles.

Authors:  C L Abad; N Safdar
Journal:  Curr Infect Dis Rep       Date:  2015-12       Impact factor: 3.725

2.  Immune activation and IL-12 production during acute/early HIV infection in the absence and presence of highly active, antiretroviral therapy.

Authors:  Adriana A Byrnes; David M Harris; Sowsan F Atabani; Beulah P Sabundayo; Susan J Langan; Joseph B Margolick; Christopher L Karp
Journal:  J Leukoc Biol       Date:  2008-09-19       Impact factor: 4.962

3.  Interleukin-12 (-1188) A/C and interferon-γ (+874) A/T gene polymorphisms in subacute sclerosing panencephalitis patients.

Authors:  Nihal Olgac Dundar; Pinar Gencpinar; Nilgun Sallakci; Ozgur Duman; Senay Haspolat; Banu Anlar; Olcay Yegin
Journal:  J Neurovirol       Date:  2016-04-21       Impact factor: 2.643

Review 4.  Emerging diseases: measles.

Authors:  Martin O Ota; William J Moss; Diane E Griffin
Journal:  J Neurovirol       Date:  2005-10       Impact factor: 2.643

5.  Interleukin (IL)-12, IL-2, interferon-gamma gene polymorphisms in subacute sclerosing panencephalitis patients.

Authors:  Vuslat Yilmaz; Veysi Demirbilek; Candan Gürses; Sibel P Yentür; Serap Uysal; Zuhal Yapici; Gülden Yilmaz; Aaron Muncey; Ozlem Cokar; Emel Onal; Aysen Gökyiğit; Güher Saruhan-Direskeneli
Journal:  J Neurovirol       Date:  2007-10       Impact factor: 2.643

6.  Hemagglutinin protein of wild-type measles virus activates toll-like receptor 2 signaling.

Authors:  Karen Bieback; Egil Lien; Ingo M Klagge; Elita Avota; Jürgen Schneider-Schaulies; W Paul Duprex; Herrmann Wagner; Carsten J Kirschning; Volker Ter Meulen; Sibylle Schneider-Schaulies
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

7.  CD46-utilizing adenoviruses inhibit C/EBPbeta-dependent expression of proinflammatory cytokines.

Authors:  Milena Iacobelli-Martinez; Ronald R Nepomuceno; Jodi Connolly; Glen R Nemerow
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

8.  Attenuation of V- or C-defective measles viruses: infection control by the inflammatory and interferon responses of rhesus monkeys.

Authors:  Patricia Devaux; Gregory Hodge; Michael B McChesney; Roberto Cattaneo
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

9.  Cell surface delivery of the measles virus nucleoprotein: a viral strategy to induce immunosuppression.

Authors:  Julien C Marie; Frédéric Saltel; Jean-Michel Escola; Pierre Jurdic; T Fabian Wild; Branka Horvat
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

10.  Identification of IFRD1 as a modifier gene for cystic fibrosis lung disease.

Authors:  YuanYuan Gu; Isaac T W Harley; Lindsay B Henderson; Bruce J Aronow; Ilja Vietor; Lukas A Huber; John B Harley; Jeffrey R Kilpatrick; Carl D Langefeld; Adrienne H Williams; Anil G Jegga; Jing Chen; Marsha Wills-Karp; S Hasan Arshad; Susan L Ewart; Chloe L Thio; Leah M Flick; Marie-Dominique Filippi; H Leighton Grimes; Mitchell L Drumm; Garry R Cutting; Michael R Knowles; Christopher L Karp
Journal:  Nature       Date:  2009-02-25       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.